NEWS R E L E A S E

Ocumetics Prepares for a Second Day of
Accommodating Intraocular Lens Implantations

For Immediate Release

Calgary, Alberta – August 26, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that it has completed the one-week postoperative examination of the first patients who were implanted with the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”). All patients are recovering well, and no complications have been observed.

With this important milestone achieved, additional individuals are now being recruited to complete the first group of patients who will be receive the Ocumetics Lens.

“This is an exciting and meaningful step forward in our mission to redefine vision correction,” said Dean Burns, President and CEO of Ocumetics Technology Corp. “Early outcomes with our first patients have been encouraging, allowing us to proceed with a second day of implantations. The real measure of success, of course, will be seen over the coming weeks when the eyes have recovered completely from surgery.”

“This moment culminates years of development,” added Dr. Garth Webb, Chief Scientist and Founder of Ocumetics. “The Ocumetics Lens has always been about restoring the full range of vision to patients. These first clinical results show that we are on the right path toward making that vision a reality.”

Unlike traditional monofocal or multifocal intraocular lenses, the Ocumetics Lens is designed to use the natural muscular activity within the eye to focus both distant and near objects clearly without glasses or contact lenses following cataract surgery.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns	Roger Jewett
President and Chief Executive Officer	Chief Financial Officer
(817) 874-7564	roger.jewett@ocumetics.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Corporation mentioned above. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.